REFERENCES
1. Perazzo H, Pacheco AG, Griep RH. Collaborators. Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort. J Hepatol 2024;80:e72-4.
2. Chalasani N, Younossi Z, Lavine JE, et al. American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American gastroenterological association, American association for the study of liver diseases, and American college of gastroenterology. Gastroenterology 2012;142:1592-609.
3. World Health Organization. No level of alcohol consumption is safe for our health. Available from: https://www.who.int/europe/news/item/04-01-2023-no-level-of-alcohol-consumption-is-safe-for-our-health [Last accessed on 28 Mar 2024].
4. Alwahsh SM, Xu M, Schultze FC, et al. Combination of alcohol and fructose exacerbates metabolic imbalance in terms of hepatic damage, dyslipidemia, and insulin resistance in rats. PLoS One 2014;9:e104220.
5. Eshraghian A, Nikeghbalian S, Dehghani M, et al. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in Iranian patients. Exp Clin Transplant 2022;20:487-94.
6. World Health Organization. World obesity day 2022-accelerating action to stop obesity. Available online: https://www.who.int/news/item/04-03-2022-world-obesity-day-2022-accelerating-action-to-stop-obesity [Last accessed on 23 Jan 2024].
7. Keramat SA, Alam K, Gow J, Biddle SJH. Impact of Disadvantaged neighborhoods and lifestyle factors on adult obesity: evidence from a 5-year cohort study in Australia. Am J Health Promot 2021;35:28-37.
8. Sun Y, Wang S, Sun X. Estimating neighbourhood-level prevalence of adult obesity by socio-economic, behavioural and built environment factors in New York City. Public Health 2020;186:57-62.
9. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism 2022;133:155217.
10. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the global burden of disease study 2013. Lancet 2014;384:766-81.
11. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389-97.e10.
12. Eslam M, Sanyal AJ, George J. International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158:1999-2014.e1.
13. Ramírez-Mejía MM, Qi X, Abenavoli L, Romero-Gómez M, Eslam M, Méndez-Sánchez N. Metabolic dysfunction: The silenced connection with fatty liver disease. Ann Hepatol 2023;28:101138.
14. Rinella ME, Lazarus JV, Ratziu V, et al. NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023;78:1966-86.
15. Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol 2022;38:251-60.
16. Cheng YM, Wang CC, Kao JH. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications. Hepatol Int 2023;17:350-6.
17. Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int 2020;40:3018-30.
18. Huang SC, Su HJ, Kao JH, et al. Clinical and histologic features of patients with biopsy-proven metabolic dysfunction-associated fatty liver disease. Gut Liver 2021;15:451-8.
19. Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol 2021;19:2138-47.e10.
21. Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol 2021;75:1284-91.
22. Ramírez-Mejía MM, Eslam M, Méndez-Sánchez N. Letter to the EDITOR: THE MAFLD and MASLD conundrum: is it reinvention of the wheel? J Hepatol 2024;79:S0168-8278(24)00158.
23. Ramírez-Mejía MM, Jiménez-Gutiérrez C, Eslam M, George J, Méndez-Sánchez N. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification? Hepatol Int 2024;18:168-78.
24. Chen L, Tao X, Zeng M, Mi Y, Xu L. Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD. J Hepatol 2024;80:e64-6.
25. Zhao Q, Deng Y. Comparison of mortality outcomes in individuals with MASLD and/or MAFLD. J Hepatol 2024;80:e62-4.
26. Wang CC, Cheng YM, Kao JH. Letter to the editor: statement of steatotic liver disease-A great leap toward the global standardization. Hepatology 2024;79:E7-8.
27. Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol 2024;80:e54-6.
28. He L, Zheng W, Qiu K, Kong W, Zeng T. Changing from NAFLD to MASLD: The new definition can more accurately identify individuals at higher risk for diabetes. J Hepatol 2024;80:e85-7.
29. Yang A, Zhu X, Zhang L, Ding Y. Transitioning from NAFLD to MAFLD and MASLD: Consistent prevalence and risk factors in a Chinese cohort. J Hepatol 2024;80:e154-5.
30. De A, Bhagat N, Mehta M, Taneja S, Duseja A. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD. J Hepatol 2024;80:e61-2.
31. Hutchison AL, Tavaglione F, Romeo S, Charlton M. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance. J Hepatol 2023;79:1524-41.
32. Wang Y, Huang Y, Antwi SO, Taner CB, Yang L. Racial disparities in liver disease mortality trends among black and white populations in the United States, 1999-2020: an analysis of CDC WONDER database. Am J Gastroenterol 2024;119:682-9.
33. Comitato R, Saba A, Turrini A, Arganini C, Virgili F. Sex hormones and macronutrient metabolism. Crit Rev Food Sci Nutr 2015;55:227-41.
34. Yuan Q, Wang H, Gao P, et al. Prevalence and risk factors of metabolic-associated fatty liver disease among 73,566 individuals in Beijing, China. Int J Environ Res Public Health 2022;19:2096.
35. Chen YL, Li H, Li S, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol 2021;21:212.
36. Chen Q, Zhao L, Mei L, et al. Association of sex hormones with hepatic steatosis in men with chronic hepatitis B. Dig Liver Dis 2022;54:378-84.
37. Liu L, Fu Q, Li T, et al. Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency. PLoS One 2022;17:e0262855.
38. Eng PC, Forlano R, Tan T, Manousou P, Dhillo WS, Izzi-Engbeaya C. Non-alcoholic fatty liver disease in women - Current knowledge and emerging concepts. JHEP Rep 2023;5:100835.
39. Anderson WD, Soh JY, Innis SE, et al. Sex differences in human adipose tissue gene expression and genetic regulation involve adipogenesis. Genome Res 2020;30:1379-92.
40. Jang YS, Joo HJ, Park YS, Park EC, Jang SI. Association between smoking cessation and non-alcoholic fatty liver disease using NAFLD liver fat score. Front Public Health 2023;11:1015919.
41. Cui Y, Zhu Q, Lou C, et al. Gender differences in cigarette smoking and alcohol drinking among adolescents and young adults in Hanoi, Shanghai, and Taipei. J Int Med Res 2018;46:5257-68.
42. Vespasiani-Gentilucci U, Valenti L, Romeo S. Usefulness of PNPLA3 variant for predicting hepatic events in steatotic liver disease: a matter of ethnicity or baseline risk? Liver Int 2023;43:2052-4.
43. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-5.
44. Wagenknecht LE, Palmer ND, Bowden DW, et al. Association of PNPLA3 with non-alcoholic fatty liver disease in a minority cohort: the insulin resistance atherosclerosis family study. Liver Int 2011;31:412-6.
45. Huang G, Wallace DF, Powell EE, Rahman T, Clark PJ, Subramaniam VN. Gene variants implicated in steatotic liver disease: opportunities for diagnostics and therapeutics. Biomedicines 2023;11:2809.
46. Goffredo M, Caprio S, Feldstein AE, et al. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: a multiethnic study. Hepatology 2016;63:117-25.
47. Semmler G, Balcar L, Wernly S, et al. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease. Front Endocrinol 2023;14:1244405.
48. Fernández-Barrena MG, Avila MA. Frontiers in fatty liver: recent advances in pathogenic mechanisms, assessment of patients' prognosis and pharmacotherapy: MASLD: new pathogenic mechanisms, risk assessment tools and drug therapies. J Physiol Biochem 2023;79:811-3.
49. Yang T, Yin J, Li J, Wang Q. The influence of different combinations of cardiometabolic risk factors on the prevalence of MASLD and risk of advanced fibrosis deserves attention. J Hepatol 2024;80:e82-5.
50. Balogun O, Wang JY, Shaikh ES, et al. Effect of combined tobacco use and type 2 diabetes mellitus on prevalent fibrosis in patients with MASLD. Hepatol Commun 2023;7:e0300.
51. Forlano R, Stanic T, Jayawardana S, et al. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies. Liver Int 2024;44:61-71.
52. Ciardullo S, Vergani M, Perseghin G. Nonalcoholic fatty liver disease in patients with type 2 diabetes: screening, diagnosis, and treatment. J Clin Med 2023;12:5597.
53. Yang G, Liu R, Rezaei S, Liu X, Wan YY. Uncovering the gut-liver axis biomarkers for predicting metabolic burden in mice. Nutrients 2023;15:3406.
54. Heller B, Reiter FP, Leicht HB, et al. Salt-intake-related behavior varies between sexes and is strongly associated with daily salt consumption in obese patients at high risk for MASLD. Nutrients 2023;15:3942.
55. Pei E, Wang H, Li Z, Xie X, Cai L, Lin M. Endoplasmic reticulum stress inhibitor may substitute for sleeve gastrectomy to alleviate metabolic dysfunction-associated steatotic liver disease. Clin Res Hepatol Gastroenterol 2023;47:102229.
56. Hepburn C, von Roenn N. Nutrition in liver disease - a review. Curr Gastroenterol Rep 2023;25:242-9.
57. Zhang X, Daniel CR, Soltero V, et al. A study of dietary patterns derived by cluster analysis and their association with metabolic dysfunction-associated steatotic liver disease severity among Hispanic patients. Am J Gastroenterol 2024;119:505-11.
58. Tamilmani P, Sathibabu Uddandrao VV, Chandrasekaran P, et al. Linalool attenuates lipid accumulation and oxidative stress in metabolic dysfunction-associated steatotic liver disease via Sirt1/Akt/PPRA-α/AMPK and Nrf-2/HO-1 signaling pathways. Clin Res Hepatol Gastroenterol 2023;47:102231.
59. Chen VL, Song MW, Suresh D, Wadhwani SI, Perumalswami P. Effects of social determinants of health on mortality and incident liver-related events and cardiovascular disease in steatotic liver disease. Aliment Pharmacol Ther 2023;58:537-45.
60. Kani AS, Ozercan A, Kani HT, Eren F, Sayar K, Yilmaz Y. Chronotype preference, sleep quality, and night-eating behaviors in patients with metabolic dysfunction-associated steatotic liver disease: assessing the relationship with disease severity and fibrosis. Hepatol Forum 2023;4:123-8.
61. Lai J, Luo L, Zhou T, Feng X, Ye J, Zhong B. Alterations in circulating bile acids in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. Biomolecules 2023;13:1356.
62. García-Mateo S, Martínez-Domínguez SJ, Gargallo-Puyuelo CJ, et al. Lifestyle can exert a significant impact on the development of metabolic complications and quality life in patients with inflammatory bowel disease. Nutrients 2023;15:3983.
63. Martínez-Domínguez SJ, García-Mateo S, Gargallo-Puyuelo CJ, et al. Inflammatory bowel disease is an independent risk factor for metabolic dysfunction-associated steatotic liver disease in lean individuals. Inflamm Bowel Dis 2023;Online ahead of print:izad175.
64. Gomaa EZ. Human gut microbiota/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek 2020;113:2019-40.
65. Chen Y, Zhou J, Wang L. Role and mechanism of gut microbiota in human disease. Front Cell Infect Microbiol 2021;11:625913.
66. Rutsch A, Kantsjö JB, Ronchi F. The gut-brain Axis: how microbiota and host inflammasome influence brain physiology and pathology. Front Immunol 2020;11:604179.
68. Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol 2019;16:690-704.
69. Shan Y, Lee M, Chang EB. The gut microbiome and inflammatory bowel diseases. Annu Rev Med 2022;73:455-68.
70. Laserna-Mendieta EJ, Clooney AG, Carretero-Gomez JF, et al. Determinants of reduced genetic capacity for butyrate synthesis by the gut microbiome in crohn's disease and ulcerative colitis. J Crohns Colitis 2018;12:204-16.
71. Milano W, De Biasio V, Di Munzio W, Foggia G, Capasso A. Obesity: The new global epidemic pharmacological treatment, opportunities and limits for personalized therapy. Endocr Metab Immune Disord Drug Targets 2020;20:1232-43.
72. Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 2018;53:362-76.
73. Chiu CC, Ching YH, Li YP, et al. Nonalcoholic fatty liver disease is exacerbated in high-fat diet-fed gnotobiotic mice by colonization with the gut microbiota from patients with nonalcoholic steatohepatitis. Nutrients 2017;9:1220.
74. Qiao S, Bao L, Wang K, et al. Activation of a specific gut bacteroides-folate-liver axis benefits for the alleviation of nonalcoholic hepatic steatosis. Cell Rep 2020;32:108005.
76. Choi KJ, Yoon MY, Kim JE, Yoon SS. Gut commensal Kineothrix alysoides mitigates liver dysfunction by restoring lipid metabolism and gut microbial balance. Sci Rep 2023;13:14668.
77. Yoshida N, Emoto T, Yamashita T, et al. Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis. Circulation 2018;138:2486-98.
78. López-Almela I, Romaní-Pérez M, Bullich-Vilarrubias C, et al. Bacteroides uniformis combined with fiber amplifies metabolic and immune benefits in obese mice. Gut Microbes 2021;13:1-20.
79. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 2016;165:1332-45.
80. Iruzubieta P, Medina JM, Fernández-López R, Crespo J, de la Cruz F. A role for gut microbiome fermentative pathways in fatty liver disease progression. J Clin Med 2020;9:1369.
81. de la Cuesta-Zuluaga J, Mueller NT, Álvarez-Quintero R, et al. Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors. Nutrients 2018;11:51.
82. Wu Y, He H, Cheng Z, Bai Y, Ma X. The role of neuropeptide y and peptide yy in the development of obesity via gut-brain axis. Curr Protein Pept Sci 2019;20:750-8.
83. Jiao N, Baker SS, Chapa-Rodriguez A, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut 2018;67:1881-91.
84. Chávez-Talavera O, Tailleux A, Lefebvre P, Staels B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 2017;152:1679-94.e3.
85. Liang Y, Chen H, Liu Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China. J Clin Endocrinol Metab 2022;107:88-97.
86. Mouries J, Brescia P, Silvestri A, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol 2019;71:1216-28.
87. Sorribas M, Jakob MO, Yilmaz B, et al. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. J Hepatol 2019;71:1126-40.
88. Chan WL, Chong SE, Chang F, et al. Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy. Hepatol Int 2023;17:870-81.
89. Ramírez-Mejía MM, Méndez-Sánchez, N. What is in a name: from NAFLD to MAFLD and MASLD-unraveling the complexities and implications. Curr Hepatology Rep 2023;22:221-7.
90. Nazir S, Jankowski V, Bender G, Zewinger S, Rye KA, van der Vorst EPC. Interaction between high-density lipoproteins and inflammation: function matters more than concentration! Adv Drug Deliv Rev 2020;159:94-119.
91. Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab 2021;50:101238.
92. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut 2022;71:778-88.
93. Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management. Cancers 2023;15:485.
94. Umar MI, Hassan W, Murtaza G, et al. The adipokine component in the molecular regulation of cancer cell survival, proliferation and metastasis. Pathol Oncol Res 2021;27:1609828.
95. Jiménez-Cortegana C, García-Galey A, Tami M, et al. Role of leptin in non-alcoholic fatty liver disease. Biomedicines 2021;9:762.
96. Deng Y, Zhao Q, Gong R. Association between metabolic associated fatty liver disease and chronic kidney disease: a cross-sectional study from NHANES 2017-2018. Diabetes Metab Syndr Obes 2021;14:1751-61.
97. Raj AS, Shanahan ER, Tran CD, et al. Dysbiosis of the duodenal mucosal microbiota is associated with increased small intestinal permeability in chronic liver disease. Clin Transl Gastroenterol 2019;10:e00068.
98. Vuik F, Dicksved J, Lam SY, et al. Composition of the mucosa-associated microbiota along the entire gastrointestinal tract of human individuals. United European Gastroenterol J 2019;7:897-907.
99. Ruan Z, Lu T, Chen Y, et al. Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults. JAMA Dermatol 2022;158:745-53.
100. Wang H, Gao Q, He S, et al. Self-reported snoring is associated with nonalcoholic fatty liver disease. Sci Rep 2020;10:9267.
101. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American college of Cardiology/American heart association task force on clinical practice guidelines. Hypertension 2018;71:1269-324.
102. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2); and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16-31.
103. Kumar R, Prakash SS, Priyadarshi RN, Anand U. Sarcopenia in chronic liver disease: a metabolic perspective. J Clin Transl Hepatol 2022;10:1213-22.
104. Mohammadi-Motlagh HR, Sadeghalvad M, Yavari N, et al. β cell and autophagy: what do we know? Biomolecules 2023;13:649.
105. Mazzotta AD, Bonci D. Advancements in hepatocellular carcinoma diagnosis and treatment: liquid biopsy and surgical as precision treatment. Hepatoma Res 2024;10:8.
106. Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019;4:389-98.
107. Pais R, Fartoux L, Goumard C, et al. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period. Aliment Pharmacol Ther 2017;46:856-63.
108. Lin L, Li Z, Yan L, Liu Y, Yang H, Li H. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019. J Hematol Oncol 2021;14:197.
109. Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018;48:696-703.
110. Zunica ERM, Heintz EC, Axelrod CL, Kirwan JP. Obesity management in the primary prevention of hepatocellular carcinoma. Cancers 2022;14:4051.
111. Abenavoli L, Scarlata GGM, Scarpellini E, et al. Metabolic-dysfunction-associated fatty liver disease and gut microbiota: from fatty liver to dysmetabolic syndrome. Medicina 2023;59:594.
112. Norero B, Dufour JF. Should we undertake surveillance for HCC in patients with MAFLD? Ther Adv Endocrinol Metab 2023;14:20420188231160389.
113. Fassio E, Barreyro FJ, Pérez MS, et al. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations? World J Hepatol 2022;14:354-71.
114. Aspichueta P, Zeisel MB. miR-21p-5p coordinates biological pathways to promote MASLD progression. Liver Int 2023;43:2343-5.
115. Abenavoli L, Scarlata GGM, Paravati MR, Boccuto L, Luzza F, Scarpellini E. Gut microbiota and liver transplantation: immune mechanisms behind the rejection. Biomedicines 2023;11:1792.
116. Wongjarupong N, Assavapongpaiboon B, Susantitaphong P, et al. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol 2017;17:149.
117. Corrao S, Natoli G, Argano C. Nonalcoholic fatty liver disease is associated with intrahepatic cholangiocarcinoma and not with extrahepatic form: definitive evidence from meta-analysis and trial sequential analysis. Eur J Gastroenterol Hepatol 2021;33:62-8.
118. De Lorenzo S, Tovoli F, Mazzotta A, et al. Non-alcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role. Cancers 2020;12:3182.
119. Pascale A, Rosmorduc O, Duclos-Vallée JC. New epidemiologic trends in cholangiocarcinoma. Clin Res Hepatol Gastroenterol 2023;47:102223.
120. Lurje I, Uluk D, Pavicevic S, et al. Body composition is associated with disease aetiology and prognosis in patients undergoing resection of intrahepatic cholangiocarcinoma. Cancer Med 2023;12:17569-80.
121. Takahashi Y, Dungubat E, Kusano H, Fukusato T. Pathology and Pathogenesis of metabolic dysfunction-associated steatotic liver disease-associated hepatic tumors. Biomedicines 2023;11:2761.
122. Maeda S, Hikiba Y, Fujiwara H, et al. NAFLD exacerbates cholangitis and promotes cholangiocellular carcinoma in mice. Cancer Sci 2021;112:1471-80.
